{
  "nctId": "NCT00244933",
  "briefTitle": "Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer",
  "officialTitle": "Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays",
  "protocolDocument": {
    "nctId": "NCT00244933",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2009-01-09",
    "uploadDate": "2022-06-15T10:25",
    "size": 341053,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT00244933/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 19,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2004-02",
    "completionDate": "2009-10",
    "primaryCompletionDate": "2008-11",
    "firstSubmitDate": "2005-10-25",
    "firstPostDate": "2005-10-27"
  },
  "eligibilityCriteria": {
    "criteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Stage IV disease\n  * Clinical and/or radiological evidence of metastatic disease\n* Measurable disease\n\n  * Prior radiotherapy allowed provided there is ≥ 1 measurable disease site outside the radiation field\n* No active CNS metastases\n\n  * Previously treated CNS metastases allowed provided disease is stable for ≥ 3 months without steroids or antiseizure medications\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* SWOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute neutrophil count ≥ 1,500/mm\\^3\n* Platelet count ≥ 100,000/mm\\^3\n* Hemoglobin ≥ 10 g/dL\n\nHepatic\n\n* Bilirubin ≤3.0 mg/dL\n* AST and ALT ≤ 2.5 times upper limit of normal\n\nRenal\n\n* Creatinine ≤ 1.5 mg/dL\n\nOther\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No serious systemic disorder that would preclude study compliance\n* No history of another malignancy except curatively treated carcinoma of the cervix or basal cell or squamous cell skin cancer in complete remission\n* No unresolved bacterial infection requiring antibiotic treatment\n* No known HIV-1 positivity\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 3 weeks since prior biologic therapy\n\nChemotherapy\n\n* Prior adjuvant chemotherapy allowed\n* Prior adjuvant or neoadjuvant taxane-based therapy or taxane therapy for metastatic disease allowed\n\n  * Patient must have failed therapy within 2 years after completion of treatment\n* At least 3 weeks since prior chemotherapy\n* No more than 2 prior cytotoxic chemotherapy regimens for metastatic disease\n* No prior gemcitabine hydrochloride\n* No other concurrent chemotherapy\n\nEndocrine therapy\n\n* See Disease Characteristics\n* At least 2 weeks since prior and no concurrent hormonal therapy\n\n  * Must have documented disease progression during prior hormonal therapy\n\nRadiotherapy\n\n* See Disease Characteristics\n* At least 4 weeks since prior radiotherapy and recovered\n* No concurrent radiotherapy\n\nSurgery\n\n* At least 3 weeks since prior surgery\n\nOther\n\n* At least 3 weeks since prior investigational therapy\n* At least 1 week since prior soy supplements (e.g., soy-based pills, liquids, or concentrates)\n\n  * Dietary soy as part of a meal (e.g., tofu) allowed once a week\n* No concurrent nutritional supplements, herbal agents, or high doses of antioxidants (e.g., vitamins C, D, or E) that may interact with, antagonize, alter, or imitate the potential effects of gemcitabine hydrochloride or genistein\n\n  * A single daily multivitamin is allowed\n* No other concurrent immunotherapy\n* No other concurrent experimental medication\n* Concurrent anticoagulants, appetite stimulants, and replacement steroids allowed",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "maximumAge": "120 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Objective Response Rate by RECIST Criteria Following",
        "description": "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
        "timeFrame": "every 2 courses until disease progression or death, up to 24 weeks"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 10,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:29:06.993Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}